pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

InSilico Medicine

updated 2mo ago
community read0 votes
pipeline
4
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(4)

pipeline depth4 products
Preclinical: 1Phase 1: 2Phase 2: 1
1Preclinical2Phase 11Phase 2
Phase 2
rentosertib acetate
Idiopathic Pulmonary Fibrosis
Phase 1
ISM-3412
Solid Tumor
Phase 1
ISM-6331
Malignant Mesothelioma
Preclinical
ISM-9274
Solid Tumor

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view InSilico Medicine jobs →

News

  • Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
    After two rejections, Replimune has made it across the regulatory finish line with its advanced melanoma therapy. Meanwhile, the last of the major pharmas, including Eli Lilly and Novo Nordisk, rep…
    biospace · 2d ago
  • After billions in deals, Insilico CEO promises: ‘You haven't seen anything yet’
    Insilico Medicine CEO Alex Zhavoronkov’s mad dash across the BIO International Convention in June attracted plenty of eyes. But the executive would prefer industry watchers gawk at the billions of…
    biospace · 3d ago
  • Why Big Pharma is chasing the industry’s most-powerful supercomputer
    Bristol Myers Squibb is the latest major drugmaker to tap Nvidia for more computing power, betting that larger models and AI agents can speed drug discovery.
    biopharma_dive · 7d ago
  • From confidence to capital: Positioning biotech for the next growth cycle
    How can biotechs be investor ready? Key takeaways from BIO International and DIA China 2026.
    biopharma_dive · 18d ago
  • How well are AI-discovered drugs faring in the clinic?
    Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted development.
    biopharma_dive · 28d ago
  • Insilico, Bora Pharma reveal plans for AI-driven manufacturing company
    Insilico Medicine and Taiwan-based CDMO Bora Pharmaceuticals are launching a new company with an AI-driven biologics manufacturing platform in a bid to compete with service providers headquartered…
    endpoints · 1mo ago
  • STAT+: AI medical devices’ dirty FDA secret
    In this edition of STAT's AI Prognosis newsletter: A look at the quirks of the most common FDA medical device approval pathway, sepsis algorithms, and more.
    stat · 3mo ago
  • STAT+: When the path to good AI is littered with bad data
    In this edition of AI Prognosis, Brittany Trang raises the question: What kind of health data would we need to train AI models to be useful in health care.
    stat · 3mo ago
  • STAT+: Why conversations around health AI may be evolving beyond hype
    In this edition of AI Prognosis, Brittany Trang argues that the tide may be turning when it comes to how the health care industry talks about AI.
    stat · 3mo ago
view all news mentions →
identifiers
source
globaldata
top tags
Oncology3Pulmonary Fibrosis1Pulmonology1
mentioned in
9news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?